MESA LABORATORIES INC /CO/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MESA LABORATORIES INC /CO/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Mar 31, 2021 | $37.96M | Jun 1, 2021 |
| FY2021 | Dec 31, 2020 | $34.17M | Jun 1, 2021 |
| FY2021 | Sep 30, 2020 | $31.86M | Jun 1, 2021 |
| FY2021 | Jun 30, 2020 | $29.94M | Jun 1, 2021 |
| FY2021 | Mar 31, 2020 | $34.21M | Jun 1, 2021 |
| FY2021 | Dec 31, 2019 | $31.66M | Jun 1, 2021 |
| FY2021 | Sep 30, 2019 | $25.54M | Jun 1, 2021 |
| FY2021 | Jun 30, 2019 | $26.29M | Jun 1, 2021 |
| FY2020 | Mar 31, 2019 | $26.45M | Jun 1, 2020 |
| FY2020 | Dec 31, 2018 | $26.68M | Jun 1, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $240.98M | May 28, 2025 |
| FY2025 | Mar 31, 2024 | $216.19M | May 28, 2025 |
| FY2025 | Mar 31, 2023 | $219.08M | May 28, 2025 |
| FY2024 | Mar 31, 2022 | $184.34M | Jun 28, 2024 |
| FY2023 | Mar 31, 2021 | $133.94M | May 30, 2023 |
| FY2022 | Mar 31, 2020 | $117.69M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | $103.14M | Jun 1, 2021 |
| FY2020 | Mar 31, 2018 | $96.18M | Jun 1, 2020 |
| FY2019 | Mar 31, 2017 | $93.67M | Jun 3, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Mar 31, 2017 | $24.30M | Jun 7, 2017 |
| FY2017 | Dec 31, 2016 | $23.84M | Jun 7, 2017 |
| FY2017 | Sep 30, 2016 | $24.41M | Jun 7, 2017 |
| FY2017 | Jun 30, 2016 | $21.11M | Jun 7, 2017 |
| FY2017 | Mar 31, 2016 | $24.81M | Jun 7, 2017 |
| FY2017 | Dec 31, 2015 | $19.91M | Jun 7, 2017 |
| FY2017 | Sep 30, 2015 | $21.78M | Jun 7, 2017 |
| FY2017 | Jun 30, 2015 | $18.16M | Jun 7, 2017 |
| FY2017 | Mar 31, 2015 | $18.56M | Jun 7, 2017 |
| FY2017 | Dec 31, 2014 | $17.83M | Jun 7, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $150.87M | May 28, 2025 |
| FY2025 | Mar 31, 2024 | $133.25M | May 28, 2025 |
| FY2025 | Mar 31, 2023 | $133.69M | May 28, 2025 |
| FY2024 | Mar 31, 2022 | $109.09M | Jun 28, 2024 |
| FY2021 | Mar 31, 2021 | $24.74M | Jun 1, 2021 |
| FY2021 | Dec 31, 2020 | $20.65M | Jun 1, 2021 |
| FY2021 | Sep 30, 2020 | $21.29M | Jun 1, 2021 |
| FY2021 | Jun 30, 2020 | $20.34M | Jun 1, 2021 |
| FY2021 | Mar 31, 2020 | $18.77M | Jun 1, 2021 |
| FY2021 | Dec 31, 2019 | $14.80M | Jun 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($1.97M) | May 28, 2025 |
| FY2025 | Mar 31, 2024 | ($254.25M) | May 28, 2025 |
| FY2025 | Mar 31, 2023 | $930.0K | May 28, 2025 |
| FY2024 | Mar 31, 2022 | $1.87M | Jun 28, 2024 |
| FY2023 | Mar 31, 2021 | $3.27M | May 30, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $16.34M | May 28, 2025 |
| FY2025 | Mar 31, 2024 | ($272.08M) | May 28, 2025 |
| FY2025 | Mar 31, 2023 | $3.32M | May 28, 2025 |
| FY2024 | Mar 31, 2022 | $4.70M | Jun 28, 2024 |
| FY2023 | Mar 31, 2021 | $12.36M | May 30, 2023 |
| FY2022 | Mar 31, 2020 | $7.92M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | $9.78M | Jun 1, 2021 |
| FY2020 | Mar 31, 2018 | $2.18M | Jun 1, 2020 |
| FY2019 | Mar 31, 2017 | $16.31M | Jun 3, 2019 |
| FY2018 | Mar 31, 2016 | $16.32M | Jun 5, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $19.52M | May 28, 2025 |
| FY2025 | Mar 31, 2024 | $19.30M | May 28, 2025 |
| FY2025 | Mar 31, 2023 | $20.49M | May 28, 2025 |
| FY2024 | Mar 31, 2022 | $15.77M | Jun 28, 2024 |
| FY2023 | Mar 31, 2021 | $10.39M | May 30, 2023 |
| FY2022 | Mar 31, 2020 | $6.36M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | $3.51M | Jun 1, 2021 |
| FY2020 | Mar 31, 2018 | $3.54M | Jun 1, 2020 |
| FY2019 | Mar 31, 2017 | $4.16M | Jun 3, 2019 |
| FY2018 | Mar 31, 2016 | $3.97M | Jun 5, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $46.81M | May 28, 2025 |
| FY2025 | Mar 31, 2024 | $44.13M | May 28, 2025 |
| FY2025 | Mar 31, 2023 | $27.98M | May 28, 2025 |
| FY2024 | Mar 31, 2022 | $39.22M | Jun 28, 2024 |
| FY2023 | Mar 31, 2021 | $37.07M | May 30, 2023 |
| FY2022 | Mar 31, 2020 | $26.99M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | $30.55M | Jun 1, 2021 |
| FY2020 | Mar 31, 2018 | $25.72M | Jun 1, 2020 |
| FY2019 | Mar 31, 2017 | $17.30M | Jun 3, 2019 |
| FY2018 | Mar 31, 2016 | $16.90M | Jun 5, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.25M | May 28, 2025 |
| FY2025 | Mar 31, 2024 | $2.57M | May 28, 2025 |
| FY2025 | Mar 31, 2023 | $4.54M | May 28, 2025 |
| FY2024 | Mar 31, 2022 | $4.43M | Jun 28, 2024 |
| FY2023 | Mar 31, 2021 | $1.99M | May 30, 2023 |
| FY2022 | Mar 31, 2020 | $1.50M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | $1.26M | Jun 1, 2021 |
| FY2020 | Mar 31, 2018 | $2.80M | Jun 1, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $433.35M | May 28, 2025 |
| FY2025 | Mar 31, 2024 | $446.80M | May 28, 2025 |
| FY2024 | Mar 31, 2023 | $661.83M | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $707.37M | May 30, 2023 |
| FY2022 | Mar 31, 2021 | $601.48M | May 31, 2022 |
| FY2021 | Mar 31, 2020 | $409.11M | Jun 1, 2021 |
| FY2020 | Mar 31, 2019 | $156.77M | Jun 1, 2020 |
| FY2019 | Mar 31, 2018 | $164.10M | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | $171.73M | Jun 5, 2018 |
| FY2017 | Mar 31, 2016 | $160.75M | Jun 7, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $273.52M | May 28, 2025 |
| FY2025 | Mar 31, 2024 | $301.40M | May 28, 2025 |
| FY2024 | Mar 31, 2023 | $268.35M | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $313.57M | May 30, 2023 |
| FY2022 | Mar 31, 2021 | $195.25M | May 31, 2022 |
| FY2021 | Mar 31, 2020 | $189.10M | Jun 1, 2021 |
| FY2020 | Mar 31, 2019 | $45.46M | Jun 1, 2020 |
| FY2019 | Mar 31, 2018 | $64.74M | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | $73.91M | Jun 5, 2018 |
| FY2017 | Mar 31, 2016 | $76.07M | Jun 7, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $159.83M | May 28, 2025 |
| FY2025 | Mar 31, 2024 | $145.39M | May 28, 2025 |
| FY2025 | Mar 31, 2023 | $393.48M | May 28, 2025 |
| FY2025 | Mar 31, 2022 | $393.80M | May 28, 2025 |
| FY2024 | Mar 31, 2021 | $406.23M | Jun 28, 2024 |
| FY2023 | Mar 31, 2020 | $220.01M | May 30, 2023 |
| FY2022 | Mar 31, 2019 | $111.31M | May 31, 2022 |
| FY2021 | Mar 31, 2018 | $99.36M | Jun 1, 2021 |
| FY2020 | Mar 31, 2017 | $97.82M | Jun 1, 2020 |
| FY2019 | Mar 31, 2016 | $84.68M | Jun 3, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $181.76M | May 28, 2025 |
| FY2025 | Mar 31, 2024 | $180.10M | May 28, 2025 |
| FY2025 | Mar 31, 2023 | $286.44M | May 28, 2025 |
| FY2024 | Mar 31, 2022 | $291.17M | Jun 28, 2024 |
| FY2023 | Mar 31, 2021 | $160.84M | May 30, 2023 |
| FY2021 | Mar 31, 2020 | $141.54M | Jun 1, 2021 |
| FY2021 | Mar 31, 2019 | $66.38M | Jun 1, 2021 |
| FY2020 | Mar 31, 2018 | $65.54M | Jun 1, 2020 |
| FY2019 | Mar 31, 2017 | $72.16M | Jun 3, 2019 |
| FY2018 | Mar 31, 2016 | $66.14M | Jun 5, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($188.94M) | May 28, 2025 |
| FY2025 | Mar 31, 2024 | ($183.49M) | May 28, 2025 |
| FY2024 | Mar 31, 2023 | $74.20M | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $76.68M | May 30, 2023 |
| FY2022 | Mar 31, 2021 | $72.46M | May 31, 2022 |
| FY2021 | Mar 31, 2020 | $72.36M | Jun 1, 2021 |
| FY2020 | Mar 31, 2019 | $73.30M | Jun 1, 2020 |
| FY2019 | Mar 31, 2018 | $68.28M | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | $73.66M | Jun 5, 2018 |
| FY2017 | Mar 31, 2016 | $64.83M | Jun 7, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $27.32M | May 28, 2025 |
| FY2025 | Mar 31, 2024 | $28.21M | May 28, 2025 |
| FY2024 | Mar 31, 2023 | $32.91M | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $49.35M | May 30, 2023 |
| FY2022 | Mar 31, 2021 | $263.87M | May 31, 2022 |
| FY2021 | Mar 31, 2020 | $81.38M | Jun 1, 2021 |
| FY2020 | Mar 31, 2019 | $10.19M | Jun 1, 2020 |
| FY2020 | Mar 31, 2018 | $5.47M | Jun 1, 2020 |
| FY2020 | Mar 31, 2017 | $5.82M | Jun 1, 2020 |
| FY2019 | Mar 31, 2016 | $5.70M | Jun 3, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $71.25M | May 28, 2025 |
| FY2019 | Mar 31, 2019 | $23.00M | Jun 3, 2019 |
| FY2018 | Mar 31, 2018 | $46.63B | Jun 5, 2018 |
| FY2017 | Mar 31, 2017 | $55.25M | Jun 7, 2017 |
| FY2016 | Mar 31, 2016 | $45.25M | Jun 6, 2016 |
| FY2015 | Mar 31, 2015 | $26.25M | Jun 3, 2015 |
| FY2014 | Mar 31, 2014 | $16.50M | Jun 4, 2014 |
| FY2014 | Mar 31, 2013 | $4.00M | Jun 4, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | May 28, 2025 |
| FY2025 | Mar 31, 2024 | (47) | May 28, 2025 |
| FY2025 | Mar 31, 2023 | 0 | May 28, 2025 |
| FY2024 | Mar 31, 2022 | 0 | Jun 28, 2024 |
| FY2021 | Mar 31, 2021 | 0 | Jun 1, 2021 |
| FY2021 | Dec 31, 2020 | 0 | Jun 1, 2021 |
| FY2021 | Sep 30, 2020 | 0 | Jun 1, 2021 |
| FY2021 | Jun 30, 2020 | 0 | Jun 1, 2021 |
| FY2021 | Mar 31, 2020 | 0 | Jun 1, 2021 |
| FY2021 | Dec 31, 2019 | (1) | Jun 1, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | May 28, 2025 |
| FY2025 | Mar 31, 2024 | (47) | May 28, 2025 |
| FY2025 | Mar 31, 2023 | 0 | May 28, 2025 |
| FY2024 | Mar 31, 2022 | 0 | Jun 28, 2024 |
| FY2021 | Mar 31, 2021 | 0 | Jun 1, 2021 |
| FY2021 | Dec 31, 2020 | 0 | Jun 1, 2021 |
| FY2021 | Sep 30, 2020 | 0 | Jun 1, 2021 |
| FY2021 | Jun 30, 2020 | 0 | Jun 1, 2021 |
| FY2021 | Mar 31, 2020 | 0 | Jun 1, 2021 |
| FY2021 | Dec 31, 2019 | (1) | Jun 1, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 5.46M | May 28, 2025 |
| FY2025 | Mar 31, 2024 | 5.39M | May 28, 2025 |
| FY2024 | Mar 31, 2023 | 5.37M | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | 5.27M | May 30, 2023 |
| FY2022 | Mar 31, 2021 | 5.14M | May 31, 2022 |
| FY2021 | Mar 31, 2020 | 4.39M | Jun 1, 2021 |
| FY2020 | Mar 31, 2019 | 3.89M | Jun 1, 2020 |
| FY2019 | Mar 31, 2018 | 3.80M | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | 3.73M | Jun 5, 2018 |
| FY2017 | Mar 31, 2016 | 3.64M | Jun 7, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Mar 31, 2015 | $2.18M | Jun 3, 2015 |
| FY2015 | Mar 31, 2014 | $1.99M | Jun 3, 2015 |
| FY2015 | Mar 31, 2013 | $1.82M | Jun 3, 2015 |
| FY2014 | Mar 31, 2012 | $1.65M | Jun 4, 2014 |
| FY2012 | Mar 31, 2011 | $1.49M | Jun 6, 2013 |